In this webinar pharmacy leaders share how hospitals are using stewardship as a sustainability strategy to control costs and ease the load on pharmacists.

Data, behavioral insights, and experimentation can be used to understand how stress, motivation, and trust shape company culture. Positively changing company culture leads to direct improvements in patient health outcomes, clinician wellbeing, and company performance.

Why more than 300,000 missing patient records reveal an engineering problem, not a policy one — and why that's good news.

Eli Lilly’s partnership with InnoCare Pharma follows deals struck this year with other China-based companies. While indications for the new alliance remain undisclosed, InnoCare specializes in oncology and autoimmune drugs.

AI could play a meaningful role in advancing social care. Not by replacing people, but by helping them and organizations doing this work move faster, see patterns earlier, and coordinate more effectively. 

Patients obtaining drugs through social media, medical spas, or telehealth platforms are not the same as patients obtaining drugs through more traditional illicit channels because they often believe what they are receiving is a clinically validated product. This means they may present with unexplained symptoms without realizing their online purchase is even relevant to the conversation

Merck now has global rights to a SciBrunch Therapeutics drug candidate designed to block mutated versions of the cancer-driving protein KRAS G12D. This class of targeted cancer therapies includes clinical-stage assets from Revolution Medicines, BridgeBio Oncology Therapeutics, and Verastem Oncology.

While SUD affects people across all demographics, a growing body of research and clinical experience makes one point clear: gender meaningfully influences how substance use develops, how it is experienced, and what supports effective treatment.

Research from MedCity News and Cotiviti shows robust AI adoption by payers and providers, but what steps are they taking for AI governance and AI weaponized cybersecurity threats?

Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum acquired Atebrioz from Incyte earlier this year.

As AI technology in healthcare becomes more deeply involved in the complex, high-stakes tasks of diagnosis and treatment planning, traditional lines of accountability will become less clear. Where does the buck stop for AI-supported medical care? 

As a country, we have developed treatments capable of improving the quality of life and preventing long-term damage for children with rheumatic conditions, yet many children cannot obtain them when they need them most. This needs to change.

What are the common reasons that a prototype fails to make the transition? There are several, but they all boil down to early-stage programs ignoring the business problem in favor of the technology problem.  

The question is whether these AI tools will be another fragmented layer of technology or true assistants to help them spend more time on patient care. 

Healthcare has a habit of embracing patient empowerment right up until patients become powerful.

The Centers for Medicare & Medicaid Services (CMS) took constructive steps in its 2027 final rule and rate announcement, particularly on payment integrity and quality measurement. But those steps are not the finish line. Policymakers should further modernize MA to strengthen competition, transparency and accountability. Here’s where to start.

Years of joint industry-academic engineering suggest that highly engineered single agents will not be the most effective treatments for solid tumors; the solution will be combining the right drugs and administering them in the right way.

Since implementing AI clinical documentation improvement (CDI) tools, Intermountain has seen a 22% point increase in inpatient chart completion during or immediately after rounds.

They see the problem first, build the fix, and decide whether it is ever adopted. The market has trained them to hide the one credential that de-risks the deal.

Electra Therapeutics’ IPO cash will support a potential first-in-class drug whose lead indication is a rare hyperinflammatory disorder with no FDA-approved treatments. Meanwhile, clinical-stage biotechs Marea Therapeutics and Sensorion revealed their respective plans to enter the U.S. public markets.

Angle Health's funding round was led by Vitruvian Partners, with participation from Town Hall Ventures, Blumberg Capital, Portage Ventures, PruVen Capital and Y Combinator.

HHS Secretary Robert F. Kennedy Jr. named eight new members to the U.S. Preventive Services Task Force this week, completing the 16-seat panel amid ongoing tension over its leadership.

What happened was not just a cybersecurity failure, it was an infrastructure failure.

This structural problem calls for a structural solution, requiring no new science, regulation, or data. 

CMS will expand its ACCESS model starting in spring 2027 to cover heart failure, COPD, substance use disorders and tobacco cessation. The outcomes-based payment model, which launched in July with 160 participating providers, will now make roughly three in four Medicare beneficiaries eligible for at least one track.

The next evolution in ADHD therapy needs to focus not only on drug efficacy but also on how treatment aligns with the ever-busy and demanding lives of patients, families, and caregivers.

The INVEST Digital Health conference, which will spotlight the consumer influence in healthcare, will include a discussion on wearables. It is scheduled for October 29 at Pegasus Park in Dallas. Register today!

Historically, warming and positioning have been addressed independently because, in many surgical procedures, they do not significantly interfere with one another. However, that’s not the case in most robotic-assisted surgeries.

Clinicians have a responsibility to understand the risks posed by AI chatbots and to inform teen patients, their parents and caregivers about them.

Pharma leaders must take a “construction crew” mindset and start treating workforce development in the same manner as they do critical infrastructure.

A new white paper from LiveWorld highlights how AI tools for healthcare marketers fall short and what’s needed for more effective marketing strategies.

A new Experian playbook shows what privacy-first activation looks like in practice, from governed onboarding through partner-enabled measurement.

If trust, transparency, and accountability remain core values in medicine, AI governance cannot be left to improvisation. 

Interra Health is helping Medicare patients access $50-per-month GLP-1s through the new Bridge program.